Helio Genomics was featured in DeciBio’s May 2026 Liquid Biopsy Round-Up, a monthly review of the most significant developments across the blood-based testing field. The round-up highlighted Helio’s commercialization partnership with Syneos Health to broaden adoption of HelioLiver, its blood-based test for the early detection of hepatocellular carcinoma (HCC).
The summary noted what sets HelioLiver apart: it uses AI to analyze cfDNA methylation patterns, protein biomarkers, and patient demographics together, an approach built specifically for catching liver cancer earlier.
Helio’s inclusion places it among the month’s most notable liquid-biopsy news alongside names like GRAIL, Natera, Guardant, and Foundation Medicine, reflecting growing industry recognition for blood-based early cancer detection.
Source: DeciBio. Read the full round-up.